Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature

BACKGROUND: Despite multidisciplinary treatment approaches, the prognosis for patients with high-grade glioma (HGG) is poor, with a median overall survival (OS) of 14.6 months for glioblastoma multiforme (GB). As high levels of vascular endothelial growth factor A (VEGF) are found in HGG, targeted a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Neurol Disord
Main Authors: Jeck, Jennifer, Kassubek, Rebecca, Coburger, Jan, Edenhofer, Simone, Schönsteiner, Stefan S., Ludolph, Albert C., Schmitz, Bernd, Engelke, Jens, Mayer-Steinacker, Regine, Lewerenz, Jan, Bullinger, Lars
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791550/
https://ncbi.nlm.nih.gov/pubmed/29403545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285617753597
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados